https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4
Skip to content 
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial, … Read more
Eli Lilly and Company (NYSE: LLY) reported its second quarter 2025 earnings results today. Worldwide revenue was $15.56 billion, up 38% from the same period a year ago. GAAP net income increased 91% to $5.6 billion, or $6.29 per share, compared to last year. Adjusted EPS rose 61% to $6.31. The company raised its full-year … Read more
An experimental pill made by Eli Lilly led to average weight loss of more than 12 percent of body weight in individuals with obesity, according to initial trial results announced by the drugmaker on Thursday. The pill is meant to be taken daily and would be an alternative to the company’s popular anti-obesity drug Zepbound, … Read more
Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, according to new data from a Phase 3 trial. The results were announced today at the annual meeting of the American Diabetes Association and published in … Read more
As of this writing, Eli Lilly & Co. (LLY) is up 16.34% on the day, making it one of the biggest gainers in the market today. The surge comes after a positive update from Bloomberg regarding its experimental weight-loss pill, orforglipron. The trial results showed that patients lost an average of 7.9% of their body … Read more
https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4